Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications assessment therapy changes drug discontinuation among crohns disease patients using
… models (cost effectiveness, budget impact) Drug utilization studies Economic burden of illness studies Epidemiology of disease Exploratory analyses of clinical trial data Global …
Communicable Diseases & Immunisation Conference 2023 Share on: Monday, June 19 - Wednesday, June 21, 2023 Conference website Research coauthored by RTI Health Solutions experts will be presented at the Communicable Diseases & Immunisation Conference …
… 2022 World Symposium on Lysosomal Disease Share on: Monday, February 7 - Friday, February 11, … will be presented at the 2022 World Symposium on Lysosomal Disease. Clinical investigator perspectives on the effects of …
… influenza, whooping cough, shingles, and pneumococcal disease. But the number vaccinated is considered suboptimal. … value of current and increased vaccination coverage among older adults for the four diseases studied. The … level of vaccine coverage would reduce the number of disease cases by over 64 million compared to no vaccine …
… validation and use of a wide variety of clinical outcome assessment instruments among patients. Ms. Pimienta’s therapeutic expertise includes … and study design to generate evidence following Food and Drug Administration (FDA)/European Medicines Agency (EMA) …
… understanding the natural history and risk factors of a disease, for providing an opportunity to observe treatments … to understand outcomes following first- and second-line therapy, identified or validated prognostic risk factors, … settings. In addition to providing the basis for multiple publications and presentations, these findings contribute …
… and thereby potentially reduce the need for CT scanning in patients with mTBI. Substantial resources are often used in assessing and treating patients with mTBI. Being able to determine the absence of … research to determine the clinical and economic impact of using such tests in the French healthcare setting by creating …
… in brain volume loss with teriflunomide versus other disease-modifying therapies in relapsing multiple sclerosis: … as well. You can reach out to Evangelia or Shahnaz using the links below. …
… local markets. Key sections in a GVD include: Value story Disease burden Unmet needs Value of the product (clinical, … Landscape How rigorously do payers manage the disease? How have payers handled reimbursement of alternative …
… we want to have the ability to replicate the research using the methods, assumptions, and data you … in such analyses. As processes have evolved to include patients and providers, we need to make it so that they can … who might make decisions based on the studies – including patients, providers, and third-party payers. Related …